|
Active, not recruiting
|
NCT02158507 -
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
|
N/A |
|
Completed
|
NCT02555657 -
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
|
Phase 3 |
|
Completed
|
NCT02834403 -
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
|
Phase 1/Phase 2 |
|
Completed
|
NCT03121352 -
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
|
Phase 2 |
|
Active, not recruiting
|
NCT03330847 -
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
|
Phase 2 |
|
Completed
|
NCT03256344 -
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
|
Phase 1 |
|
Recruiting
|
NCT04739670 -
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
|
Phase 2 |
|
Withdrawn
|
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A |
|
Completed
|
NCT01238952 -
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
|
Phase 1 |
|
Completed
|
NCT03577743 -
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
|
Phase 2 |
|
Completed
|
NCT03411161 -
S 81694 Plus Paclitaxel in Metastatic Breast Cancer
|
Phase 1/Phase 2 |
|
Withdrawn
|
NCT04149444 -
A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
|
Phase 2 |
|
Withdrawn
|
NCT05008510 -
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
|
Phase 2 |
|
Completed
|
NCT04111510 -
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
|
Phase 2 |
|
Recruiting
|
NCT05029999 -
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
|
Phase 1 |
|
Recruiting
|
NCT03709446 -
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
|
Phase 1/Phase 2 |